Online inquiry

IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6263MR)

This product GTTS-WQ6263MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6263MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14909MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ4621MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ15120MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ5347MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ5456MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ14786MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ12745MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ13972MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW